Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment

Circulating cell‐free DNA (cfDNA) contains circulating tumor DNA (ctDNA), which can be obtained from serial liquid biopsies to enable tumor genome analysis throughout the course of treatment. We investigated cfDNA and mutant ctDNA as potential biomarkers to predict the best outcomes of regorafenib‐t...

Full description

Bibliographic Details
Main Authors: Brice Pastor, Thierry André, Julie Henriques, Isabelle Trouilloud, Christophe Tournigand, Marine Jary, Thibault Mazard, Christophe Louvet, Simon Azan, Audrey Bauer, Benoit Roch, Cynthia Sanchez, Dewi Vernerey, Alain R. Thierry, Antoine Adenis
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Molecular Oncology
Subjects:
circulating DNA
colorectal cancer
predictive biomarker
regorafenib
tumor response
Online Access:https://doi.org/10.1002/1878-0261.12972

Internet

https://doi.org/10.1002/1878-0261.12972

Similar Items